Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Naftifine Gel Study Group.
Three hundred and sixteen patients with a diagnosis of tinea pedis were evaluated in two multicenter, double-blind randomized studies. One hundred and fifty-nine patients applied naftifine gel 1 percent and 157 applied gel vehicle to affected areas twice daily for four weeks. At the end of treatment, the naftifine-treated groups had higher mycologic cure rates (66 percent and 63 percent) than the respective vehicle-treated groups (34 percent and 27 percent, p is less than 0.01 and p is less than 0.001). The rate of global improvement in patients' conditions and the reduction in the incidence and severity of most signs and symptoms was greater for naftifine-treated patients in both studies. The results of these studies indicate that twice-daily use of naftifine gel 1 percent is safe and significantly more effective than vehicle in the treatment of tinea pedis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000499:Allylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D014677:Pharmaceutical Vehicles; D012074:Remission Induction; D013997:Time Factors; D014008:Tinea Pedis / Q000188:drug therapy*
D000935:Antifungal Agents; D005782:Gels; D014677:Pharmaceutical Vehicles; D000499:Allylamine; C029178:naftifine